Innate Pharma S.A. (EPA:IPH)
France · Delayed Price · Currency is EUR 1.588
-0.006 (-0.38%)
Sep 11, 2026, 5:35 PM CET
Innate Pharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Strong Buy" and an average price target of €5.90. The average 1-year stock price forecast is 271.54% higher than the current stock price, while the lowest is €5.60 (+252.64%) and the highest is €6.20 (+290.43%).
Price Target: €5.90 (+271.54%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 1 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
55.26M
from 9.01M
Increased by 513.63%
Revenue Next Year
109.36M
from 55.26M
Increased by 97.91%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.